CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape

Cell Reports

Volumn 15, Issue 3, 2016, Pages 481-489

  Wang, Zhen ^a,b   Pan, Qinghua ^a   Gendron, Patrick ^c   Zhu, Weijun ^d   Guo, Fei ^d   Cen, Shan ^e   Wainberg, Mark A ^a,b   Liang, Chen ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d INSTITUTE OF PATHOGEN BIOLOGY   (China)

^e INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAS9 PROTEIN; CRISPR ASSOCIATED PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA END JOINING REPAIR; DNA SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS GENOME; VIRUS IMMUNITY; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS REPLICATION; CELL LINE; CRISPR CAS SYSTEM; GENE EDITING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNE EVASION; INDEL MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

BASE SEQUENCE; CELL LINE; CRISPR-CAS SYSTEMS; DNA, VIRAL; GENE EDITING; HIV-1; HUMANS; IMMUNE EVASION; INDEL MUTATION; MUTATION; VIRUS REPLICATION;

EID: 84962726170     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.042     Document Type: Article

References (39)

1. Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D.A., Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315:1709-1712.
2. Bi Y., Sun L., Gao D., Ding C., Li Z., Li Y., Cun W., Li Q. High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog. 2014, 10:e1004090.
3. Bolger A.M., Lohse M., Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014, 30:2114-2120.
4. Bolotin A., Quinquis B., Sorokin A., Ehrlich S.D. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 2005, 151:2551-2561.
5. Cho S.W., Kim S., Kim J.M., Kim J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31:230-232.
6. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
7. Dampier W., Nonnemacher M.R., Sullivan N.T., Jacobson J.M., Wigdahl B. HIV excision utilizing CRISPR/Cas9 technology: attacking the proviral quasispecies in reservoirs to achieve a cure. MOJ Immunol. 2014, 1:00022.
8. Dong C., Qu L., Wang H., Wei L., Dong Y., Xiong S. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 2015, 118:110-117.
9. Ebina H., Misawa N., Kanemura Y., Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 2013, 3:2510.
10. Holmes M., Zhang F., Bieniasz P.D. Single-cell and single-cycle analysis of HIV-1 replication. PLoS Pathog. 2015, 11:e1004961.
11. Hsu P.D., Lander E.S., Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157:1262-1278.
12. Hu W., Kaminski R., Yang F., Zhang Y., Cosentino L., Li F., Luo B., Alvarez-Carbonell D., Garcia-Mesa Y., Karn J., et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 2014, 111:11461-11466.
13. Jern P., Russell R.A., Pathak V.K., Coffin J.M. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 2009, 5:e1000367.
14. Jiang F., Zhou K., Ma L., Gressel S., Doudna J.A. Structural Biology. A Cas9-guide RNA complex preorganized for target DNA recognition. Science 2015, 348:1477-1481.
15. Jinek M., East A., Cheng A., Lin S., Ma E., Doudna J. RNA-programmed genome editing in human cells. eLife 2013, 2:e00471.
16. Karimova M., Beschorner N., Dammermann W., Chemnitz J., Indenbirken D., Bockmann J.H., Grundhoff A., Lüth S., Buchholz F., Schulze zur Wiesch J., Hauber J. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci. Rep. 2015, 5:13734.
17. Kennedy E.M., Cullen B.R. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology 2015, 479-480:213-220.
18. Kennedy E.M., Kornepati A.V., Goldstein M., Bogerd H.P., Poling B.C., Whisnant A.W., Kastan M.B., Cullen B.R. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J. Virol. 2014, 88:11965-11972.
19. Kennedy E.M., Bassit L.C., Mueller H., Kornepati A.V., Bogerd H.P., Nie T., Chatterjee P., Javanbakht H., Schinazi R.F., Cullen B.R. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 2015, 476:196-205.
20. Li C., Guan X., Du T., Jin W., Wu B., Liu Y., Wang P., Hu B., Griffin G.E., Shattock R.J., Hu Q. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J. Gen. Virol. 2015, 96:2381-2393.
21. Liao H.K., Gu Y., Diaz A., Marlett J., Takahashi Y., Li M., Suzuki K., Xu R., Hishida T., Chang C.J., et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat. Commun. 2015, 6:6413.
22. Lin S.R., Yang H.C., Kuo Y.T., Liu C.J., Yang T.Y., Sung K.C., Lin Y.Y., Wang H.Y., Wang C.C., Shen Y.C., et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids 2014, 3:e186.
23. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
24. Manjunath N., Yi G., Dang Y., Shankar P. Newer gene editing technologies toward HIV gene therapy. Viruses 2013, 5:2748-2766.
25. Mojica F.J., Díez-Villaseñor C., García-Martínez J., Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 2005, 60:174-182.
26. Pourcel C., Salvignol G., Vergnaud G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 2005, 151:653-663.
27. Ramanan V., Shlomai A., Cox D.B., Schwartz R.E., Michailidis E., Bhatta A., Scott D.A., Zhang F., Rice C.M., Bhatia S.N. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci. Rep. 2015, 5:10833.
28. Sanjana N.E., Shalem O., Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 2014, 11:783-784.
29. Schopman N.C., ter Brake O., Berkhout B. Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology 2010, 7:52.
30. Seeger C., Sohn J.A. Targeting hepatitis B virus with CRISPR/Cas9. Mol. Ther. Nucleic Acids 2014, 3:e216.
31. Suenaga T., Kohyama M., Hirayasu K., Arase H. Engineering large viral DNA genomes using the CRISPR-Cas9 system. Microbiol. Immunol. 2014, 58:513-522.
32. Wang J., Quake S.R. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc. Natl. Acad. Sci. USA 2014, 111:13157-13162.
33. Wang J., Xu Z.W., Liu S., Zhang R.Y., Ding S.L., Xie X.M., Long L., Chen X.M., Zhuang H., Lu F.M. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J. Gastroenterol. 2015, 21:9554-9565.
34. Wang G., Zhao N., Berkhout B., Das A.T. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol. Ther. 2016, 24:522-526.
35. Yuan M., Zhang W., Wang J., Al Yaghchi C., Ahmed J., Chard L., Lemoine N.R., Wang Y. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J. Virol. 2015, 89:5176-5179.
36. Yuen K.S., Chan C.P., Wong N.H., Ho C.H., Ho T.H., Lei T., Deng W., Tsao S.W., Chen H., Kok K.H., Jin D.Y. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J. Gen. Virol. 2015, 96:626-636.
37. Zhen S., Hua L., Takahashi Y., Narita S., Liu Y.H., Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem. Biophys. Res. Commun. 2014, 450:1422-1426.
38. Zhen S., Hua L., Liu Y.H., Gao L.C., Fu J., Wan D.Y., Dong L.H., Song H.F., Gao X. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther. 2015, 22:404-412.
39. Zhu W., Lei R., Le Duff Y., Li J., Guo F., Wainberg M.A., Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015, 12:22.